Literature DB >> 2309035

A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients.

G Chouinard1, L Beauclair, R Geiser, P Etienne.   

Abstract

1. Nine severe rapid cycling manic-depressive patients were treated with a magnesium preparation, Magnesiocard 40 mEq/day in an open label study for a period up to 32 weeks. 2. Magnesiocard was found to have clinical results at least equivalent to those of lithium in about 50% of these patients. These results were obtained in an exploratory study and should be interpreted with caution. 3. The possibility that Magnesiocard could replace or improve the efficacy of lithium as a preventive treatment of manic-depressive illness merits further clinical investigation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309035     DOI: 10.1016/0278-5846(90)90099-3

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

1.  Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction.

Authors:  A A Spasov; I N Iezhitsa; M S Kravchenko; M V Kharitonova
Journal:  Neurosci Behav Physiol       Date:  2009-07-21

Review 2.  The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review.

Authors:  Neil Bernard Boyle; Clare Lawton; Louise Dye
Journal:  Nutrients       Date:  2017-04-26       Impact factor: 5.717

3.  A fully integrated new paradigm for lithium's mode of action - lithium utilizes latent cellular fail-safe mechanisms.

Authors:  Arthur Ernst van Woerkom
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-31       Impact factor: 2.570

4.  Effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammatory biomarkers, and SIRT1 in obese women: a study protocol for a double-blind, randomized, placebo-controlled trial.

Authors:  Behnaz Abiri; Mohammadreza Vafa
Journal:  Trials       Date:  2020-02-26       Impact factor: 2.279

Review 5.  Rapid cycling bipolar disorder: Literature review on pharmacological treatment illustrated by a case report on ketamine.

Authors:  Alexis Bourla; Florian Ferreri; Thomas Baudry; Vincent Panizzi; Vladimir Adrien; Stéphane Mouchabac
Journal:  Brain Behav       Date:  2022-01-18       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.